NEW ORLEANS — LumiThera announced it has entered into a definitive merger agreement with Diopsys, according to a press release.
In the agreement, Diopsys stockholders will receive stock in LumiThera, and Diopsys will become a wholly owned subsidiary of LumiThera.
“As of this morning, we announced Diopsys and LumiThera are going to merge to form a theranostic company for dry age-related macular degeneration and other degenerative ocular disease and damage,” Clark Tedford, CEO of LumiThera, told Healio/OSN in a video recorded at the Eyecelerator meeting here.